1. Africa to receive 300m doses of Russian vaccine  GhanaWeb
  2. Russia approves its third COVID-19 vaccine, CoviVac  The Indian Express
  3. Coronavirus: Ghana approves Russia's Sputnik V vaccine for emergency use  GhanaWeb
  4. The Russians and the Chinese are touting their vaccines. Should we trust them?  The Washington Post
  5. View Full coverage on Google News
Africa Vaccine Acquisition Task Team (AVATT) has received an offer of 300 million doses of Russia’s Sputnik V vaccine.Africa Vaccine Acquisition Task Team (AVATT) has received an offer of 300 million doses of Russia’s Sputnik V vaccine.

Africa to receive 300m doses of Russian vaccine

Sputnik V was approved in August and late-stage trials began in September. Mass vaccination was launched in December, after preliminary trial results showed the vaccine to be 91.4% effective.Sputnik V was approved in August and late-stage trials began in September. Mass vaccination was launched in December, after preliminary trial results showed the vaccine to be 91.4% effective.

Russia approves its third COVID-19 vaccine, CoviVac | World News,The Indian Express

Sputnik V was approved in August and late-stage trials began in September. Mass vaccination was launched in December, after preliminary trial results showed the vaccine to be 91.4% effective.Sputnik V was approved in August and late-stage trials began in September. Mass vaccination was launched in December, after preliminary trial results showed the vaccine to be 91.4% effective.

Russia approves its third COVID-19 vaccine, CoviVac | World News,The Indian Express

The global vaccine rollout has not been free from geopolitical rivalries and point-scoring.The global vaccine rollout has not been free from geopolitical rivalries and point-scoring.

Vaccine diplomacy: how some countries are using COVID to enhance their soft power

Vaccine diplomacy: how some countries are using COVID to enhance their soft power

No definite date has been set for the procurement of Russian-made COVID-19 (coronavirus disease 2019) Sputnik V while both Manila and Moscow are discussing a possible government-to-government” deal, Philippine Ambassador to Moscow Carlos Soreta said on Monday.

PH, Russia still threshing out Sputnik V vaccine deal – Manila Bulletin

MOSCOW, Feb 20: Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though la...MOSCOW, Feb 20: Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though la...

Russia approves its third COVID-19 vaccine

Russia has approved its third domestically produced coronavirus vaccine, although large-scale clinical trials have yet to be completed. Russia has approved its third domestically produced coronavirus vaccine, although large-scale clinical trials have yet to be completed.

Russia Approves CoviVac, Its Third Coronavirus Vaccine

Russia has registered its third COVID-19 vaccine CoviVac, following Sputnik V and EpiVacCorona, Prime Minister Mikhail Mishustin announced on Saturday.

Russia registers 3rd COVID-19 vaccine - Global Times

According to the manual, other contraindications include severe allergic reactions According to the manual, other contraindications include severe allergic reactions

Inoculation against coronavirus with CoviVac contraindicated during pregnancy - Society & Culture - TASS

Inoculation against coronavirus with CoviVac contraindicated during pregnancy

The vaccine can help restore the organism’s ‘immune memory’ and boost immunity when it begins to lower in ten to twelve months post-Covid, according to the researcherThe vaccine can help restore the organism’s ‘immune memory’ and boost immunity when it begins to lower in ten to twelve months post-Covid, according to the researcher

CoviVac to be recommended for booster immunization, expert says - Society & Culture - TASS

CoviVac to be recommended for booster immunization, expert says

Russia will produce 88 million vaccine doses in the first half of this year, including 83 million doses of its Sputnik V shot, Russian Deputy Prime Minister Tatiana Golikova said on state TV on Saturday.Russia will produce 88 million vaccine doses in the first half of this year, including 83 million doses of its Sputnik V shot, Russian Deputy Prime Minister Tatiana Golikova said on state TV on Saturday.

Russia to produce 88 million COVID-19 vaccine doses in first half: deputy PM | Reuters

Last August, Russia's Sputnik V became the first registered vaccine against COVID-19 in the world, while approval of EpiVacCorona followed in October.Last August, Russia's Sputnik V became the first registered vaccine against COVID-19 in the world, while approval of EpiVacCorona followed in October.

Russia Registers Its Third Vaccine Against Coronavirus - Sputnik International

A third Covid-19 vaccine has been registered in Russia, the country's Prime Minister Mikhail Mishustin announced on Saturday morning. The drug, dubbed CoviVac, has been developed by the Chumakov Scientific Center in Moscow.A third Covid-19 vaccine has been registered in Russia, the country's Prime Minister Mikhail Mishustin announced on Saturday morning. The drug, dubbed CoviVac, has been developed by the Chumakov Scientific Center in Moscow.

Russia registers THIRD domestically-created vaccine against Covid-19, PM reveals: New jab CoviVac joins Sputnik V & EpiVacCorona — RT Russia & Former Soviet Union

As opposed to existing Sputnik V and EpiVacCorona shots, the new CoviVac jab produced by a state-run research center uses an inactive virusAs opposed to existing Sputnik V and EpiVacCorona shots, the new CoviVac jab produced by a state-run research center uses an inactive virus

Russia registers third COVID-19 vaccine | The Times of Israel

The first 120,000 doses will be put into civilian circulation in mid-March, the prime minister saidThe first 120,000 doses will be put into civilian circulation in mid-March, the prime minister said

Russia registers its third COVID-19 vaccine CoviVac - Society & Culture - TASS

Russia registers its third COVID-19 vaccine CoviVac

MOSCOW (Reuters) – Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though large-scale clinical trials of the shot, labelled CoviVac and produced by the Chumakov Centre, have yet to begin. Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, developed by … Continued

Russia approves its third COVID-19 vaccine: PM - Egypt Independent

Russia has approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin says, athough large-scale clinical trials of the shot have...Russia has approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin says, athough large-scale clinical trials of the shot have...

Russia approves third vaccine | Moree Champion | Moree, NSW

The Russian government has approved its third domestically developed coronavirus vaccine.The Russian government has approved its third domestically developed coronavirus vaccine.

Russia approves third domestic COVID-19 vaccine | NHK WORLD-JAPAN News

Russia has already approved two COVID-19 vaccines, Sputnik V and EpiVacCorona, which were also granted approval before seeing any late-stage trial resultsRussia has already approved two COVID-19 vaccines, Sputnik V and EpiVacCorona, which were also granted approval before seeing any late-stage trial results

Russia approves third COVID-19 vaccine - CoviVac- Business News

Russia has registered its third vaccine against Covid-19, the country's Prime Minister announced Saturday, promising to accelerate production rates. "From theRussia has registered its third vaccine against Covid-19, the country's Prime Minister announced Saturday, promising to accelerate production rates. "From the middle of March, the first 120,

Russia registers third coronavirus vaccine

Russia has already approved two Covid-19 vaccines following a similar approach of granting approval before seeing any late-stage trial results.Russia has already approved two Covid-19 vaccines following a similar approach of granting approval before seeing any late-stage trial results.

Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a similar approach of granting approval before seeing any late-stage trial results.Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a similar approach of granting approval before seeing any late-stage trial results.

Russia Approves Its Third COVID-19 Vaccine: PM Mikhail Mishustin

Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though large-scale clinical trials of the shot, labelled CoviVac and produced by the Chumakov Centre, have yet to begin.Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though large-scale clinical trials of the shot, labelled CoviVac and produced by the Chumakov Centre, have yet to begin.

Russia Approves Its Third Covid-19 Vaccine for Domestic Use: PM Mikhail Mishustin

Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, following a similar approach of granting approval before seeing any late-stage trial results.Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, following a similar approach of granting approval before seeing any late-stage trial results.

Russia approves 3rd coronavirus vaccine before late-stage trials begin, PM says - National | Globalnews.ca

The CoviVac vaccine is made of a coronavirus that has been inactivated, or stripped of its ability to replicate.. Read more at straitstimes.com.Europe News -The CoviVac vaccine is made of a coronavirus that has been inactivated, or stripped of its ability to replicate.. Read more at straitstimes.com.

Russia approves its third Covid-19 vaccine, CoviVac, Europe News & Top Stories - The Straits Times

Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a similar approach of granting approval before seeing any late-stage trial results.Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a similar approach of granting approval before seeing any late-stage trial results.

Russia approves its third COVID-19 vaccine: Prime Minister Mikhail Mishustin - The Economic Times

Experts say Sputnik V gives around 92 percent protection against the common coronavirus variant. Experts say Sputnik V gives around 92 percent protection against the common coronavirus variant.

Africa to receive 300m doses of Russian vaccine - The East African

By Polina Ivanova MOSCOW (Reuters) - Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though large-scale clinical trials of the shot, labelled CoviVac and produced by the Chumakov Centre, have yet to begin. Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a similar approach of granting approval before seeing any late-stage trial results. The preemptive approvals had raised concerns among some scientists in the West, but inoculations with those first two shots began on a mass scale in Russia only after trials were concluded and showed success. Sputnik V was approved in August and late-stage trials began in September. Mass vaccination was launched in December, after preliminary trial results showed the vaccine to be 91.4% effective. Since then, more than two million Russians have been vaccinated with at least the first dose of Sputnik V, Health Minister Mikhail Murashko said on Feb. 10. Rollout of a second vaccine, developed by the Vector Institute in Novosibirsk, is beginning. Today, Russia is the only country to have already three vaccines against COVID-19, Prime Minister Mishustin said. The Chumakov Centre, founded in 1955 in St Petersburg by Mikhail Chumakov, is known for its work with U.S. scientist Albert Sabin at the height of the Cold War, which led to the production of the widely-used polio vaccine. DIFFERENT TYPE OF VACCINE Unlike the Sputnik V vaccine, which uses a modified harmless cold virus that tricks the body into producing antigens to help the immune system prepare for a coronavirus infection, the CoviVac vaccine is a whole-virion vaccine. This means it is made of a coronavirus that has been inactivated, or stripped of its ability to replicate. The vaccine we have developed... reflects the whole history of Russian, as well as global, vaccine science, the Chumakov Centre's director, Aidar Ishmukhametov, said on Saturday. The advantage, according to virologist Alexander Chepurnov, cited by outlet Lenta.Ru, is that CoviVac includes all elements of the virus, creating a broader immune response that is likely to protect against any variants. However, testing Russia's COVID-19 shots against SARS-CoV-2 variants that have emerged in the UK, South Africa and elsewhere is in its early stages. President Vladimir Putin on Monday ordered a review of Russia's COVID-19 vaccines to be presented by March 15 assessing their ability to protect against the new variants. RESULTS SO FAR Globally, one other major vaccine candidate - India's COVAXIN by Bharat Biotech - uses the whole-virion approach. India's drug regulator has touted the shot's ability to act against the whole body of a virus instead of just its spike-protein tip, potentially making it more effective in case of mutations. The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit), Deputy Prime Minister Tatiana Golikova said in a government briefing in January. The shot has already been tested for safety on 200 people aged between 18 and 60, Ishmukhametov told the state-run Vesti-24 news channel in late January. This early-stage trial began on Sept. 21 last year, according to the state clinical trials register. It showed no side-effects, including no rise in temperature, Ishmukhametov said. Mid-stage trials to test volunteers' immune responses were ongoing, he said at the time. Only a placebo-controlled, large-scale trial could ascertain effectiveness, he added. This is due to begin now that the go-ahead has been granted. The first 120,000 doses, however, will be produced and released to the national inoculation programme in March, Mishustin said. Then, the Chumakov Centre will produce around half a million doses per month on its platforms, Ishmukhametov said on Saturday. Deputy Prime Minister Golikova also announced on Saturday that Russia will produce 88 million vaccine doses in the first half of this year, including 83 million Sputnik V doses. (Reporting by Polina Ivanova; Additional reporting by Darya Korsunskaya and Gleb Stolyarov; Editing by Nick Macfie, Kate Kelland and Frances Kerry)By Polina Ivanova MOSCOW (Reuters) - Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though large-scale clinical trials of the shot, labelled CoviVac and produced by the Chumakov Centre, have yet to begin. Russia has already approved two COVID-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a similar approach of granting approval before seeing any late-stage trial results. The preemptive approvals had raised concerns among some scientists in the West, but inoculations with those first two shots began on a mass scale in Russia only after trials were concluded and showed success. Sputnik V was approved in August and late-stage trials began in September. Mass vaccination was launched in December, after preliminary trial results showed the vaccine to be 91.4% effective. Since then, more than two million Russians have been vaccinated with at least the first dose of Sputnik V, Health Minister Mikhail Murashko said on Feb. 10. Rollout of a second vaccine, developed by the Vector Institute in Novosibirsk, is beginning. "Today, Russia is the only country to have already three vaccines against COVID-19," Prime Minister Mishustin said. The Chumakov Centre, founded in 1955 in St Petersburg by Mikhail Chumakov, is known for its work with U.S. scientist Albert Sabin at the height of the Cold War, which led to the production of the widely-used polio vaccine. DIFFERENT TYPE OF VACCINE Unlike the Sputnik V vaccine, which uses a modified harmless cold virus that tricks the body into producing antigens to help the immune system prepare for a coronavirus infection, the CoviVac vaccine is a "whole-virion" vaccine. This means it is made of a coronavirus that has been inactivated, or stripped of its ability to replicate. "The vaccine we have developed... reflects the whole history of Russian, as well as global, vaccine science," the Chumakov Centre's director, Aidar Ishmukhametov, said on Saturday. The advantage, according to virologist Alexander Chepurnov, cited by outlet Lenta.Ru, is that CoviVac includes all elements of the virus, creating a broader immune response that is likely to protect against any variants. However, testing Russia's COVID-19 shots against SARS-CoV-2 variants that have emerged in the UK, South Africa and elsewhere is in its early stages. President Vladimir Putin on Monday ordered a review of Russia's COVID-19 vaccines to be presented by March 15 assessing their ability to protect against the new variants. RESULTS SO FAR Globally, one other major vaccine candidate - India's COVAXIN by Bharat Biotech - uses the "whole-virion" approach. India's drug regulator has touted the shot's ability to act against the whole body of a virus instead of just its "spike-protein" tip, potentially making it more effective in case of mutations. The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit), Deputy Prime Minister Tatiana Golikova said in a government briefing in January. The shot has already been tested for safety on 200 people aged between 18 and 60, Ishmukhametov told the state-run Vesti-24 news channel in late January. This early-stage trial began on Sept. 21 last year, according to the state clinical trials register. It showed no side-effects, including no rise in temperature, Ishmukhametov said. Mid-stage trials to test volunteers' immune responses were ongoing, he said at the time. Only a placebo-controlled, large-scale trial could ascertain effectiveness, he added. This is due to begin now that the go-ahead has been granted. The first 120,000 doses, however, will be produced and released to the national inoculation programme in March, Mishustin said. Then, the Chumakov Centre will produce around half a million doses per month on its platforms, Ishmukhametov said on Saturday. Deputy Prime Minister Golikova also announced on Saturday that Russia will produce 88 million vaccine doses in the first half of this year, including 83 million Sputnik V doses. (Reporting by Polina Ivanova; Additional reporting by Darya Korsunskaya and Gleb Stolyarov; Editing by Nick Macfie, Kate Kelland and Frances Kerry)

The large-scale clinical trials of the shot have yet to beginThe large-scale clinical trials of the shot have yet to begin

Russia approves its third COVID-19 vaccine, CoviVac | Europe – Gulf News

Moscow promised to introduce the new jab to the population by March.Moscow promised to introduce the new jab to the population by March.

Russia Says Registers Third Coronavirus Vaccine - The Moscow Times